MEI Pharma

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its products include Zandelisib, Voruciclib, and ME-344. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.

As of late, it has definitely been a great time to be an investor in MEI Pharma, Inc. (MEIP).

MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue?

SAN DIEGO and TOKYO, May 14, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical...

MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress

MEI Pharma Set To Explode With Announcement Of Lucrative Partnership

A10 Networks

Ensign Group

Gaia

Turning Point Brands

Despite the coronavirus-induced market downturn, a handful of stocks have soared in the last seven trading days defying the overall market trend.

5 Top Stocks That Have Skyrocketed in the Past 7 Days

DaVita

KalVista Pharma

ResMed

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

New Covid-19 Cases Increase, 5 Defensive Stocks to Buy

MEI Pharma (MEIP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

MEI Pharma (MEIP) Catches Eye: Stock Jumps 8.1%

MEI Pharma, Inc. (MEIP) CEO Daniel Gold on Q4 2019 Results - Earnings Call Transcript

MEI Pharma is back at support levels where there has been significant buying interest - including a large private placement in 2018 that stoked a rally.

MEI Pharma: Time To Reload At Key Support Level

MEI Pharma (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: MEI Pharma (MEIP) Q3 Earnings Expected to Decline

News for MEI Pharma Stock (MEIP)